secwatch.observer — SEC 8-K summary
======================================

Issuer:     Whitehawk Therapeutics, Inc. (WHWK)
CIK:        0001422142
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0001628280-23-028411
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aadi Bioscience Q2 FYARRO sales $6.2M (+80% YoY); advancing PRECISION1 and new trials
--------------------------------------------------------------------------------

- FYARRO net product sales $6.2M in Q2 2023, up ~6% QoQ and 80% YoY from $3.4M.
- Net loss $18.0M for Q2 2023 (vs $18.3M prior year); cash $134.9M expected to fund into 2025.
- PRECISION1 trial interim analysis on 40 patients with appropriate follow-up expected before end of 2023.
- Phase 2 trials in endometrial cancer (nab-sirolimus + letrozole) and NETs to initiate in Q4 2023.
- First patient dosed in Phase 1/2 KRAS G12C trial with adagrasib (Mirati collaboration).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422142/000162828023028411/0001628280-23-028411-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422142/000162828023028411/aadi-20230809.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-028411

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer